Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Gross Margin came in at 75.97% in Q1 2026, down 321.0% YoY from 34.38% in Q1 2025, and down 18.73% on a QoQ basis from 93.48% in Q4 2025.
Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 5 years of Gross Margin data on file, last reported at 75.97% in Q1 2026.
- Quarterly Gross Margin fell 321.0% year-over-year to 75.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 96.12% (up 1588.0% YoY) and the FY2025 annual result came in at 82.44%, down 127.0% from the prior year.
- Gross Margin slipped to 75.97% in Q1 2026, from 93.48% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 204.98% in Q4 2023 to a low of 1665.24% in Q2 2023.
- A 5-year average of 20.94% and a median of 88.29% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin sank 176524 bps — and 2024, when it surged 174909 bps.
- Tracing ATRA's Gross Margin over 5 years: stood at 100.0% in 2022, then soared by 105 bps to 204.98% in 2023, then tumbled by 61 bps to 79.25% in 2024, then grew by 18 bps to 93.48% in 2025, then decreased by 19 bps to 75.97% in 2026.
- The last three Gross Margin figures came in at 75.97% (Q1 2026), 93.48% (Q4 2025), and 96.67% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | 69.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.68% |
| Mar 31, 2026 | 75.97% |
| Dec 31, 2025 | 93.48% |
| Sep 30, 2025 | 96.67% |
| Jun 30, 2025 | 96.85% |
| Mar 31, 2025 | 79.18% |
| Dec 31, 2024 | 79.25% |
| Sep 30, 2024 | 81.08% |
| Jun 30, 2024 | 83.84% |
| Mar 31, 2024 | 92.74% |
| Dec 31, 2023 | 204.98% |
| Sep 30, 2023 | -29.46% |
| Jun 30, 2023 | -1,665.24% |
| Mar 31, 2023 | 75.57% |
| Dec 31, 2022 | 100.00% |
| Sep 30, 2022 | 100.00% |
| Jun 30, 2022 | 100.00% |